Urinary markers for prostate cancer

BJU International

Volumn 99, Issue 2, 2007, Pages 263-268

  Downes, Michelle R ^a,b   Byrne, Jennifer C ^b   Pennington, Stephen R ^b   Dunn, Michael J ^b   Fitzpatrick, John M ^b   Watson, R William G ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Marker; Prostate cancer; Proteomics; Urine

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; 8 HYDROXYDEOXYGUANOSINE; BIOLOGICAL MARKER; CALGRANULIN; DNA MARKER; GLUTATHIONE TRANSFERASE P1; INHIBIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN; RNA; TELOMERASE; THROMBOPLASTIN; THYMOSIN; THYMOSIN BETA15; TRANSFERRIN; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER SCREENING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE MARKER; DNA METHYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MEDICAL RESEARCH; MEDLINE; NON INVASIVE PROCEDURE; NUCLEIC ACID AMPLIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TUMOR BIOPSY; URINALYSIS; URINE;

DNA, NEOPLASM; HUMANS; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEOMICS; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33846191201     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06610.x     Document Type: Short Survey

References (53)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics 2003. CA Cancer J Clin 2003; 53: 5-26
2. Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate 1990; 16: 39-48
3. Boyle P, Maisonneuve P, Napalkov P. Incidence of prostate cancer will double by the year 2030: the argument for. Eur Urol 1996; 29 (Suppl. 2): 3-9
4. Pannek J, Partin AW. Prostate-specific antigen: what's new in 1997. Oncology (Williston Park) 1997; 11: 1273-82
5. Partin AW, Osterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994; 152: 1358-68
6. Anonymous. Screening for prostate cancer. American College of Physicians. Ann Int Med 1991; 126: 480-4
7. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low PSA levels. J Urol 2000; 163: 806-12
8. Christensson A, Bjork T, Nilsson O et al. Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-5
9. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum PSA. J Urol 1992; 147: 817-21
10. Oesterling JE, Cooner WH, Jacobsen SJ, Guess HA, Lieber MM. Influence of patient age on the serum concentration of prostate specific antigen: an important clinical observation. Urol Clin North Am 1993; 20: 671-80
11. Harden SV, Guo Z, Epstein JL, Sidransky D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostatic adenocarcinoma. J Urol 2003; 169: 1138-42
12. Goessl C, Krause H, Muller M et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000; 60: 5941-5
13. Cairns P, Esteller M, Hernan JG et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 2001; 7: 2727-30
14. Jeronimo C, Usadel R, Henrique R et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002; 60: 1131-5
15. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation. analysis of postbiopsy urine specimens. Clin Cancer Res 2003; 9: 2673-2
16. Goessl C, Muller M, Heicappell R et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 2001; 58: 335-8
17. Crocitto LE, Korns D, Kretzner L et al. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology 2004; 64: 821-5
18. Hoque MO, Topaloglu O, Begum S et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005; 23: 6569-75
19. Thuret R, Chantel-Groussard K, Azzouzi AR et al. Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer. Br J Cancer 2005; 92: 236-40
20. Cussenot O, Teillac P, Berthon P, Latil A. Noninvasive detection of genetic instability in cells from prostatic secretion as a marker of prostate cancer. Eur J Intern Med 2001; 12: 17-9
21. Chiou CC, Chang PY, Chan EC, Wu TL, Tsao KC, Wu JT. Urinary 8-hydroxydeoxyguanosine and its analogs as DNA marker of oxidative stress: development of an ELISA and measurement in both bladder and prostate cancers. Clin Chim Acta 2003; 334: 87-94
22. Jeronimo C, Nomoto S, Caballero OL et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 2001; 20: 5195-8
23. Bussemakers MJ, van Bokhoven A, Verhaegh GW et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9
24. de Kok JB, Verhaegh GW, Roelofs RW et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumours. Cancer Res 2002; 62: 2695-8
25. Fradet Y, Saad F, Aprikian A et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004; 64: 311-6
26. Hessels D, Klein-Gunnewiek JM, van Oort I et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-16
27. Wang H, Xi X, Kong X, Huang G, Ge G. The expression and significance of survivin mRNA in urinary bladder carcinomas. J Cancer Res Clin Oncol 2004; 130: 487-90
28. Zielie PJ, Mobley JA, Ebb RG, Jiang Z, Blute RD, Ho SM. A novel diagnostic test for prostate cancer emerges from the determination of α-methylacylcoenzyme A racemase in prostatic secretions. J Urol 2004; 172: 1130-3
29. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996; 56: 218-22
30. Kallakury BV, Brien TP, Lowry CV et al. Telomerase activity in human benign prostatic tissue and prostatic adenocarcinomas. Diagn Mol Pathol 1997; 6: 192-8
31. Botchkina GI, Kim RH, Botchkina IL, Kirshenbaum A, Frischer Z, Adler HL. Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity. Clin Cancer Res 2005; 11: 3243-9
32. Hutchinson LM, Chang EL, Becker CM et al. Use of Thymosin β15 as a urinary biomarker in human prostate cancer. Prostate 2005; 64: 116-27
33. Hutchinson LM, Chang EL, Becker CM et al. Development of a sensitive and specific enzyme-linked immunosorbent assay for thymosin β15, a urinary biomarker of human prostate cancer. Clin Biochem 2005; 38: 558-71
34. Bao L, Loda M, Janmey PA, Stewart R, Anand-Apte B, Zetter BR. Thymosin β15: a novel regulator of tumour cell motility upregulated in metastatic prostate cancer. Nat Med 1996; 2: 1322-8
35. Rogers CG, Yan Y, Zha S et al. Prostate cancer detection on urinalysis for alpha-methylacyl coenzyme A racemase protein. J Urol 2004; 172: 1501-3
36. Meid FH, Gygi CM, Leisinger HJ, Bosman FT, Benhattar J. The use of telomerase activity for the detection of prostate cancer cells after prostatic massage. J Urol 2001; 165: 1802-5
37. Vicentini C, Gravina GL, Angelucci A et al. Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia. J Cancer Res Clin Oncol 2004; 130: 217-21
38. Teni TR, Sheth AR, Kamath MR, Sheth NA. Serum and urinary prostatic inhibin-like peptide in benign prostatic hyperplasia and carcinoma of prostate. Cancer Lett 1988; 43: 9-14
39. Lwaleed BA, Francis JL, Chisholm M. Urinary tissue factor levels in patients with bladder and prostate cancer. Eur J Surg Oncol 2000; 26: 44-9
40. Adamson AS, Francis JL, Witherow RO, Snell ME. Urinary tissue factor levels in prostatic carcinoma: a potential marker of metastatic spread. Br J Urol 1993; 71: 587-92
41. Fernandez C, Rifai N, Wenger AS, Mickey DD, Silverman LM. A preliminary study of urinary transferrin as a marker for prostate cancer. Clin Chim Acta 1986; 161: 335-9
42. van Dieijen-Visser MP, Hendriks MW, Delaere KP, Gijzen AH, Brombacher PJ. The diagnostic value of urinary transferrin compared to serum prostate specific antigen (PSA) and prostate acid phosphatase (PAP) in patients with prostate cancer. Clin Chim Acta 1988; 177: 77-80
43. Graves HC, Sensabaugh GF, Blake ET. Postcoital detection of a male-specific semen protein. Application to the investigation of rape. N Engl J Med 1985; 312: 338-43
44. Iwakiri J, Grandbois K, Wehner N, Graves HC, Stamey T. An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands. J Urol 1993; 149: 783-6
45. Irani J, Salomon L, Soulie M et al. Urine/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection. Urology 2005; 65: 533-7
46. Irani J, Millet C, Levillian P, Dore B, Begon F, Aubert J. Serum-to-urinary prostate specific antigen ratio: its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 ng/ml. J Urol 1997; 157: 185-8
47. Pannek J, Rittenhouse HG, Evans CL et al. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology 1997; 50: 715-21
48. Stoeber K, Swinn R, Prevost AT et al. Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. J Natl Cancer Inst 2002; 94: 1071-9
49. Tanaka M, Tanaka T, Matsuzaki S et al. Rapid and quantitative detection of human septin family Bradeion as a practical diagnostic method of colorectal and urologic cancers. Med Sci Monit 2003; 9: MT61-8
50. Lombardo ME, Hudson PB. Preliminary evaluation of 5α-reductase type 2 in urine as potential marker for prostate disease. Steroids 1997; 62: 682-5
51. Rehman I, Azzouzi AR, Catto JW et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 2004; 64: 1238-43
52. Tremblay J, Frenette G, Tremblay RR, Dupont A, Thabet M, Dube JY. Excretion of three major prostatic secretory proteins in the urine of normal men and patients with benign prostatic hypertrophy or prostate cancer. Prostate 1987; 10: 235-43
53. Downes MR, Byrne JC, Dunn MJ et al. Application of proteomic strategies to the identification of urinary biomarkers for prostate cancer: a review. Biomarkers 2006; 11: 406-16